Drug targets for Cancer: SLAMF7

Drug Targets for Cancer: SLAMF7 and Cancer

Studies with SLAMF7-specific CARs confirmed the suitability of SLAMF7 as a potential target in Multiple myeloma (MM). Both NK cells and T cells expressing second-generation CARs based on a single chain variable fragment of an antibody related to elotuzumab effectively redirected NK and T cells to secrete cytokines, degranulate and exhibit cytotoxic activity in response to MM cell lines and primary human myeloma cells in vitro. SLAMF7-directed NK and T cells also inhibited tumor growth and prolonged survival in an orthotopic MM xenograft mouse model.

Drug Targets for Cancer: SLAMF7 related Products

Other vital drug targets for cancer like SLAMF7:

Drug Targets for Cancer: SLAMF7 Related Reference

Einsele H, Schreder M. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab. Therapeutic Advances in Hematology. 2016;7(5):288-301.

Drug Targets for Cancer: SLAMF7 Related Information